Skip to main content
Signal8
Launch Terminal

OnKure Therapeutics, Inc. (OKUR)

OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc.

NASDAQ:OKURHealthcare
-2.33%$2.52
AH Close$2.52+0.00%vs close
Mkt Cap$102.05M
Float24.9M
O/S40.5M
Inst Own86.1%
SI4.9%
Dilution
OnKure Therapeutics, Inc. logoNASDAQ:OKUR$2.52-2.33%
FormDescription
13G
Beneficial Ownership Report
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
4/A
Statement of Changes in Beneficial Ownership
8-K
5.02,9.01
3
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
13G/A
Beneficial Ownership Report (Amended)
424B5
Prospectus Supplement
3
8-K
2.02,9.01
3
10-Q
Quarterly Report
7
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership

1-25 of 402

…